Literature DB >> 28208168

Strategies for Targeted Therapy in Head and Neck Squamous Cell Carcinoma Using WEE1 Inhibitor AZD1775.

Michael Kao1, Carlos Green1, Julia Sidorova2, Eduardo Méndez1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28208168      PMCID： PMC5824224          DOI： 10.1001/jamaoto.2016.4563

Source DB:  PubMed          Journal:  JAMA Otolaryngol Head Neck Surg        ISSN： 2168-6181            Impact factor:   6.223


× No keyword cloud information.
  4 in total

1.  Analysis of protein dynamics at active, stalled, and collapsed replication forks.

Authors:  Bianca M Sirbu; Frank B Couch; Jordan T Feigerle; Srividya Bhaskara; Scott W Hiebert; David Cortez
Journal:  Genes Dev       Date:  2011-06-15       Impact factor: 11.361

2.  Functional kinomics identifies candidate therapeutic targets in head and neck cancer.

Authors:  Russell Moser; Chang Xu; Michael Kao; James Annis; Luisa Angelica Lerma; Christopher M Schaupp; Kay E Gurley; In Sock Jang; Asel Biktasova; Wendell G Yarbrough; Adam A Margolin; Carla Grandori; Christopher J Kemp; Eduardo Méndez
Journal:  Clin Cancer Res       Date:  2014-08-15       Impact factor: 12.531

3.  Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.

Authors:  Marieke Aarts; Rachel Sharpe; Isaac Garcia-Murillas; Heidrun Gevensleben; Melissa S Hurd; Stuart D Shumway; Carlo Toniatti; Alan Ashworth; Nicholas C Turner
Journal:  Cancer Discov       Date:  2012-04-23       Impact factor: 39.397

4.  Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease.

Authors:  Raquel Domínguez-Kelly; Yusé Martín; Stephane Koundrioukoff; Marvin E Tanenbaum; Veronique A J Smits; René H Medema; Michelle Debatisse; Raimundo Freire
Journal:  J Cell Biol       Date:  2011-08-22       Impact factor: 10.539
  4 in total
  6 in total

1.  Multiple Defects Sensitize p53-Deficient Head and Neck Cancer Cells to the WEE1 Kinase Inhibition.

Authors:  Ahmed Diab; Michael Kao; Keffy Kehrli; Hee Yeon Kim; Julia Sidorova; Eduardo Mendez
Journal:  Mol Cancer Res       Date:  2019-01-24       Impact factor: 5.852

2.  A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma.

Authors:  Eduardo Méndez; Cristina P Rodriguez; Michael C Kao; Sharat Raju; Ahmed Diab; R Alex Harbison; Eric Q Konnick; Ganesh M Mugundu; Rafael Santana-Davila; Renato Martins; Neal D Futran; Laura Q M Chow
Journal:  Clin Cancer Res       Date:  2018-03-13       Impact factor: 12.531

3.  FOXM1 drives HPV+ HNSCC sensitivity to WEE1 inhibition.

Authors:  Ahmed Diab; Hakan Gem; Jherek Swanger; Hee Yeon Kim; Kaleb Smith; Grace Zou; Sharat Raju; Michael Kao; Matthew Fitzgibbon; Keith R Loeb; Cristina P Rodriguez; Eduardo Méndez; Denise A Galloway; Julia M Sidorova; Bruce E Clurman
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-22       Impact factor: 11.205

4.  Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.

Authors:  Joshua D Campbell; Christina Yau; Reanne Bowlby; Yuexin Liu; Kevin Brennan; Huihui Fan; Alison M Taylor; Chen Wang; Vonn Walter; Rehan Akbani; Lauren Averett Byers; Chad J Creighton; Cristian Coarfa; Juliann Shih; Andrew D Cherniack; Olivier Gevaert; Marcos Prunello; Hui Shen; Pavana Anur; Jianhong Chen; Hui Cheng; D Neil Hayes; Susan Bullman; Chandra Sekhar Pedamallu; Akinyemi I Ojesina; Sara Sadeghi; Karen L Mungall; A Gordon Robertson; Christopher Benz; Andre Schultz; Rupa S Kanchi; Carl M Gay; Apurva Hegde; Lixia Diao; Jing Wang; Wencai Ma; Pavel Sumazin; Hua-Sheng Chiu; Ting-Wen Chen; Preethi Gunaratne; Larry Donehower; Janet S Rader; Rosemary Zuna; Hikmat Al-Ahmadie; Alexander J Lazar; Elsa R Flores; Kenneth Y Tsai; Jane H Zhou; Anil K Rustgi; Esther Drill; Ronglei Shen; Christopher K Wong; Joshua M Stuart; Peter W Laird; Katherine A Hoadley; John N Weinstein; Myron Peto; Curtis R Pickering; Zhong Chen; Carter Van Waes
Journal:  Cell Rep       Date:  2018-04-03       Impact factor: 9.423

5.  Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer.

Authors:  Bo Mi Ku; Yeon-Hee Bae; Jiae Koh; Jong-Mu Sun; Se-Hoon Lee; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn
Journal:  Oncotarget       Date:  2017-06-28

Review 6.  Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers.

Authors:  Mary Glorieux; Rüveyda Dok; Sandra Nuyts
Journal:  Oncotarget       Date:  2017-09-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.